在印度消除淋巴丝虫病的大规模用药辅助病媒控制战略的成本效益

Donald S. Shepard, Aung K. Lwin, Sunish I. Pulikkottil, Mariapillai Kalimuthu, Natarajan Arunachalam, Brij K. Tyagi, Graham B. White
{"title":"在印度消除淋巴丝虫病的大规模用药辅助病媒控制战略的成本效益","authors":"Donald S. Shepard, Aung K. Lwin, Sunish I. Pulikkottil, Mariapillai Kalimuthu, Natarajan Arunachalam, Brij K. Tyagi, Graham B. White","doi":"10.1101/2023.12.10.23299653","DOIUrl":null,"url":null,"abstract":"Background/Methodology: Despite progress using mass drug administration (MDA), lymphatic filariasis (LF) remains a major public health issue in India. Vector control (VC) is hypothesized as a potentially useful addition to MDA towards LF elimination. We conducted cost-effectiveness analysis of MDA alone and augmented by VC single (VCS) or integrated VC approaches (VCI). Data came from historical controls and a 3-arm cluster randomized trial of 36 villages at risk of LF transmission in Tamil Nadu, India. The arms were: MDA alone (the standard of care); VCS (MDA plus expanded polystyrene beads for covering the water surface in wells and cesspits to suppress the filariasis vector mosquito Culex quinquefasciatus), and VCI (VCS plus insecticidal pyrethroid impregnated curtains over windows, doors, and eaves). Economic costs in 2010 US$ combined government and community inputs from household to state levels. Outcomes were controlled microfilaria prevalence (MfP) and antigen prevalence (AgP) to conventional elimination targets (MfP<1% and AgP<2%) from 2010 to 2013, and disability adjusted life years (DALYs) averted.\nPrincipal Findings: The estimated annual economic cost per resident was US$0.53 for MDA alone, US$1.02 for VCS, and US$1.83 for VCI. With MDA offered in all arms, all reduced LF prevalence substantially and significantly from 2010 to 2013. MDA proved highly cost effective at $112 per DALY, a very small (8%) share of India's then per capita GDP. Progress towards elimination was comparable across all three study arms.\nConclusions: The well-functioning MDA was effective and very cost-effective for eliminating LF, leaving little scope for further improvement. Supplementary VC demonstrated no statistically significant additional benefit in this trial.","PeriodicalId":501072,"journal":{"name":"medRxiv - Health Economics","volume":"19 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cost-effectiveness of vector control strategies for supplementing mass drug administration for eliminating lymphatic filariasis in India\",\"authors\":\"Donald S. Shepard, Aung K. Lwin, Sunish I. Pulikkottil, Mariapillai Kalimuthu, Natarajan Arunachalam, Brij K. Tyagi, Graham B. White\",\"doi\":\"10.1101/2023.12.10.23299653\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background/Methodology: Despite progress using mass drug administration (MDA), lymphatic filariasis (LF) remains a major public health issue in India. Vector control (VC) is hypothesized as a potentially useful addition to MDA towards LF elimination. We conducted cost-effectiveness analysis of MDA alone and augmented by VC single (VCS) or integrated VC approaches (VCI). Data came from historical controls and a 3-arm cluster randomized trial of 36 villages at risk of LF transmission in Tamil Nadu, India. The arms were: MDA alone (the standard of care); VCS (MDA plus expanded polystyrene beads for covering the water surface in wells and cesspits to suppress the filariasis vector mosquito Culex quinquefasciatus), and VCI (VCS plus insecticidal pyrethroid impregnated curtains over windows, doors, and eaves). Economic costs in 2010 US$ combined government and community inputs from household to state levels. Outcomes were controlled microfilaria prevalence (MfP) and antigen prevalence (AgP) to conventional elimination targets (MfP<1% and AgP<2%) from 2010 to 2013, and disability adjusted life years (DALYs) averted.\\nPrincipal Findings: The estimated annual economic cost per resident was US$0.53 for MDA alone, US$1.02 for VCS, and US$1.83 for VCI. With MDA offered in all arms, all reduced LF prevalence substantially and significantly from 2010 to 2013. MDA proved highly cost effective at $112 per DALY, a very small (8%) share of India's then per capita GDP. Progress towards elimination was comparable across all three study arms.\\nConclusions: The well-functioning MDA was effective and very cost-effective for eliminating LF, leaving little scope for further improvement. Supplementary VC demonstrated no statistically significant additional benefit in this trial.\",\"PeriodicalId\":501072,\"journal\":{\"name\":\"medRxiv - Health Economics\",\"volume\":\"19 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Health Economics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2023.12.10.23299653\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Health Economics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2023.12.10.23299653","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景/方法:尽管在大规模给药(MDA)方面取得了进展,但淋巴丝虫病(LF)仍然是印度的一个主要公共卫生问题。病媒控制(VC)被认为是MDA消除LF的潜在有用补充。我们进行了MDA单独、VC单一(VCS)或VC综合方法(VCI)增强的成本-效果分析。数据来自印度泰米尔纳德邦36个有LF传播风险的村庄的历史对照和三组随机试验。两组分别为:MDA单独治疗(标准治疗);VCS(丙二醛加膨胀聚苯乙烯珠,用于覆盖水井和污水池的水面,以抑制致倦库蚊)和VCI(丙二醛加杀虫剂拟除虫菊酯浸渍在窗户、门和屋檐上的窗帘)。2010年的经济成本为美元,从家庭到州各级政府和社区投入的总和。结果是2010 - 2013年微丝蚴患病率(MfP)和抗原患病率(AgP)控制在常规消除目标(MfP<1%和AgP<2%),并避免残疾调整生命年(DALYs)。主要发现:人均年经济成本估计仅MDA为0.53美元,VCS为1.02美元,VCI为1.83美元。在2010年至2013年期间,所有部队都提供了MDA,大大降低了LF患病率。MDA被证明具有很高的成本效益,每DALY 112美元,占印度当时人均GDP的份额很小(8%)。在所有三个研究组中,消除进展是可比性的。结论:功能良好的MDA对于消除LF是有效且非常经济的,几乎没有进一步改善的余地。在这项试验中,补充VC没有显示出统计学上显著的额外益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cost-effectiveness of vector control strategies for supplementing mass drug administration for eliminating lymphatic filariasis in India
Background/Methodology: Despite progress using mass drug administration (MDA), lymphatic filariasis (LF) remains a major public health issue in India. Vector control (VC) is hypothesized as a potentially useful addition to MDA towards LF elimination. We conducted cost-effectiveness analysis of MDA alone and augmented by VC single (VCS) or integrated VC approaches (VCI). Data came from historical controls and a 3-arm cluster randomized trial of 36 villages at risk of LF transmission in Tamil Nadu, India. The arms were: MDA alone (the standard of care); VCS (MDA plus expanded polystyrene beads for covering the water surface in wells and cesspits to suppress the filariasis vector mosquito Culex quinquefasciatus), and VCI (VCS plus insecticidal pyrethroid impregnated curtains over windows, doors, and eaves). Economic costs in 2010 US$ combined government and community inputs from household to state levels. Outcomes were controlled microfilaria prevalence (MfP) and antigen prevalence (AgP) to conventional elimination targets (MfP<1% and AgP<2%) from 2010 to 2013, and disability adjusted life years (DALYs) averted. Principal Findings: The estimated annual economic cost per resident was US$0.53 for MDA alone, US$1.02 for VCS, and US$1.83 for VCI. With MDA offered in all arms, all reduced LF prevalence substantially and significantly from 2010 to 2013. MDA proved highly cost effective at $112 per DALY, a very small (8%) share of India's then per capita GDP. Progress towards elimination was comparable across all three study arms. Conclusions: The well-functioning MDA was effective and very cost-effective for eliminating LF, leaving little scope for further improvement. Supplementary VC demonstrated no statistically significant additional benefit in this trial.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Co-developing a comprehensive disease policy model with stakeholders: the case of malaria during pregnancy How does participation in coal-to-gas policy and availability of natural gas pipelines affect residents' well-being? Causally-informative analyses of the effect of job displacement on all-cause and specific-cause mortality from the 1990s Finnish recession until 2020: A population registry study Privacy Protection of Sexually Transmitted Infections Information from Chinese Electronic Medical Records Quantifying the health impact of crop breeding: Revisiting the Disability-Adjusted Life Years Approach
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1